论文部分内容阅读
进展期肝细胞癌的切除率不高，作者根据早期设计的完全门静脉游离和碳粒灌注（HVI－CHP）系统治疗进展期肝细胞癌的经验，大剂量化疗药物仅进入肝脏．经肝动脉注入阿霉素的肝和全身最大耐受量为每次治疗150mg／m2，肿瘤有效反应率为64％。作者现扩大治疗范围，28例肝细胞癌多数
The rate of resection of advanced hepatocellular carcinoma is not high. The authors used the experience of the early design of the complete portal vein free and carbon-perfusion (HVI-CHP) system to treat advanced hepatocellular carcinoma. High-dose chemotherapy drugs only enter the liver. The liver and systemic maximal tolerated dose of doxorubicin injected via the hepatic artery was 150 mg/m2 per treatment, and the effective tumor response rate was 64%. The authors now expand the scope of treatment, 28 cases of hepatocellular carcinoma majority